Anticoagulant

P2Y12 inhibitor plus anti-coagulation vs. anticoagulation alone in noncritically ill patients with COVID-19.

Among patients with nonvalvular atrial fibrillation, those with frailty were less likely to receive an anticoagulant and, if anticoagulated, were more likely to receive warfarin than a direct oral anticoagulant, researchers reported.

Among young patients with provoked venous thromboembolism, shorter duration of anticoagulation is noninferior to current standard of care, according to the results of the Kids-DOTT randomized trial.

In a cohort of noncritically ill patients with COVID-19, the addition of a P2Y12 inhibitor to anticoagulation did not extend survival or lessen disease severity, according to results of the ACTIV-4a trial.

Many patients undergoing transcatheter aortic valve replacement have multiple thrombotic and bleeding-related comorbidities that make optimal antiplatelet and anticoagulant management complex, leaving the question of which strategies are best open to debate.

A study assessing anticoagulant use in patients on hemodialysis who were diagnosed with atrial fibrillation revealed 81.5% did not initiate treatment with any anticoagulant within 30 days of being diagnosed.

Patients who continued to use anticoagulant therapy beyond the initial 3 to 6 months of treatment for a first unprovoked venous thromboembolism were at “considerable” risk for major bleeding, researchers wrote.

For patients with atrial fibrillation, the risk for AKI was lower in those who were prescribed a direct oral anticoagulant than in those prescribed warfarin.

Rivaroxaban (Xarelto, Janssen/Bayer)-based therapeutic anticoagulation vs. standard of care in patients with COVID-19.

Adults prescribed any oral anticoagulation therapy have lower bone mineral density and trabecular bone score compared with controls, with a stronger negative effect observed among those prescribed warfarin, data published in Bone show.